Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer.
Brennen WN, Zhu Y, Coleman IM, Dalrymple SL, Antony L, Patel RA, Hanratty B, Chikarmane R, Meeker AK, Zheng SL, Hooper JE, Luo J, De Marzo AM, Corey E, Xu J, Yegnasubramanian S, Haffner MC, Nelson PS, Nelson WG, Isaacs WB, Isaacs JT.
Brennen WN, et al.
JCI Insight. 2021 Apr 22;6(8):e146827. doi: 10.1172/jci.insight.146827.
JCI Insight. 2021.
PMID: 33724955
Free PMC article.